Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,028.00
Bid: 12,032.00
Ask: 12,036.00
Change: 98.00 (0.82%)
Spread: 4.00 (0.033%)
Open: 12,108.00
High: 12,142.00
Low: 11,994.00
Prev. Close: 11,930.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-German COVID-19 cases are growing exponentially again -RKI

Tue, 16th Mar 2021 06:36

* Epidemiologist says 'irrational' to loosen restrictions

* Merkel, state leaders allowed phased easing of curbs

* City of Berlin puts on hold plans for further easing
(Adds Berlin stopping further easing of lockdown)

BERLIN, March 16 (Reuters) - Coronavirus infections are
rising exponentially in Germany, an expert at the Robert Koch
Institute for infectious diseases said on Tuesday, putting at
risk plans to lift the lockdown and revive the economy.

The number of cases per 100,000 reported on Tuesday was
83.7, up from 68 a week ago, and the RKI has said that metric
could reach 200 by the middle of next month.

Germany is definitely in a third wave of the pandemic,
driven by the fact it has loosened restrictions in recent weeks
just as a more transmissable variant has spread, Dirk Brockmann,
an epidemiologist at the RKI, told Germany's ARD television.

"It has been totally irrational to loosen up here. It is
just fuelling this exponential growth," he said.

Chancellor Angela Merkel and state leaders agreed a phased
easing of curbs earlier this month along with an "emergency
brake" to let authorities reimpose restrictions if case numbers
rise above 100 per 100,000 on three consecutive days.

They are due to meet again on March 22 to discuss whether to
allow any further relaxation of the rules.

The state government in the city of Berlin decided on
Tuesday to put on hold any more easing, such as allowing
restaurants or cinemas to open, the Tagesspiegel newspaper
reported.

VACCINATION WOES

Germany's decision on Monday to suspend AstraZeneca's
vaccine could delay progress in reaching herd immunity
and postpone an economic recovery in the second quarter,
analysts said.

The decision follows seven cases of thrombosis in Germany,
including three deaths, and delivers a major setback to the
country's drive to speed up its sluggish vaccination campaign.

A planned meeting between Merkel and state leaders on
Wednesday to discuss using family doctors to administer COVID-19
vaccines has been postponed until after the European Medicines
Agency completes its review into the AstraZeneca shot.

AstraZeneca has said an analysis of its safety data covering
reported cases from over 17 million vaccine doses given had
shown no evidence of an increased risk of pulmonary embolism,
deep vein thrombosis or low levels of platelets.

The RKI's Brockmann noted that 1,000 people in a million had
died of COVID-19, compared to possibly 1 in a million from
complications associated with the vaccine.

"In the risk groups, the risk of dying of COVID is much,
much higher. That means it is probably 100,000 times more likely
to die of COVID than because of an AstraZeneca vaccine," he
said.
(Reporting by Emma Thomasson and Caroline Copley, Editing by
Timothy Heritage and Gareth Jones)

More News
Today 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
Today 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more
21 May 2024 12:03

CORRECT: Stocks fall but pound up as IMF ups UK forecast

(Correcting London Stock Exchange index prices.)

Read more
21 May 2024 12:00

LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast

(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.

Read more
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
21 May 2024 09:04

LONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall

(Alliance News) - Stock prices in London opened in the red on Tuesday, with some US interest rate cut optimism cooling after hawkish words from Federal Reserve central bankers.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.